# Shinkyo Yoon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/shinkyo-yoon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,755 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 24 |
| i10-index | 46 |
| Last Known Institution | Ulsan College |
| OpenAlex ID | https://openalex.org/A5022408548 |
| ORCID iD | 0000-0001-7544-0404 |
| Works | 136 |

## Researcher papers

- [Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/incidence-of-pseudoprogression-during-immune-checkpoint-inhibitor-therapy-for/)
- [Suicide in cancer patients within the first year of diagnosis](https://scholariq.org/papers/suicide-in-cancer-patients-within-the-first-year-of-diagnosis/)
- [Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors](https://scholariq.org/papers/definition-incidence-and-challenges-for-assessment-of-hyperprogressive-disease/)
- [Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib](https://scholariq.org/papers/cross-sectional-study-of-imatinib-plasma-trough-levels-in-patients-with-advanced/)
- [Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation](https://scholariq.org/papers/enhanced-glycolysis-supports-cell-survival-in-egfr-mutant-lung-adenocarcinoma-by/)
- [Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma](https://scholariq.org/papers/radiomics-based-prediction-model-for-outcomes-of-pd-1-pd-l1-immunotherapy-in/)
- [Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients](https://scholariq.org/papers/bevacizumab-plus-erlotinib-combination-therapy-for-advanced-hereditary/)
- [Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer](https://scholariq.org/papers/integrative-analysis-of-risk-factors-for-immune-related-adverse-events-of/)
- [Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era](https://scholariq.org/papers/prognostic-significance-of-serum-beta-2-microglobulin-in-patients-with-diffuse/)
- [Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/comparison-of-recist-1-1-and-irecist-in-patients-treated-with-immune-checkpoint/)
- [Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice](https://scholariq.org/papers/efficacy-safety-and-resistance-profile-of-osimertinib-in-t790m-mutation-positive/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Ulsan College](https://scholariq.org/institutions/ulsan-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.